As bstract. We have tested the participation of endogenous opiate pathways in the negative feedback actions of gonadal steroids on pulsatile properties of luteinizing (LH) hormone release in normal men. To this end, sex steroid hormones were infused intravenously at dosages that under steady state conditions selectively suppressed either the frequency or the amplitude of the pulsatile LH signal. The properties of pulsatile LH secretion were assessed quantitatively by computerized analysis of LH series derived from serial blood sampling over 12 h of observation.
As bstract. We have tested the participation of endogenous opiate pathways in the negative feedback actions of gonadal steroids on pulsatile properties of luteinizing (LH) hormone release in normal men. To this end, sex steroid hormones were infused intravenously at dosages that under steady state conditions selectively suppressed either the frequency or the amplitude of the pulsatile LH signal. The properties of pulsatile LH secretion were assessed quantitatively by computerized analysis of LH series derived from serial blood sampling over 12 h of observation.
When the pure (nonaromatizable) androgen, 5-a-dihydrotestosterone, was infused continuously for 108 h at the blood production rate of testosterone, we were able to achieve selective inhibition ofLH pulse frequency akin to that observed in experimental animals after low-dosage androgen replacement. Under these conditions, serum concentrations of testosterone and estradiol-1 7,3 did not change significantly, but serum 5a-dihydrotestosterone concentrations increased approximately two-to threefold, with a corresponding increase in levels of its major me-tabolite, 5a-androstan-3a, 17f-diol. In separate experiments, the infusion of estradiol-1 7#3 at its blood production rate over a 4.5-d interval selectively suppressed LH pulse amplitude without influencing LH pulse frequency. Estrogen infusion increased serum estradiol-1 73 levels approximately twofold without significantly altering blood androgen concentrations. We then used these schedules of selective androgen or estrogen infusion to investigate the participation of endogenous opiates in the individual inhibitory feedback actions of pure androgen or estrogen on pulsatile LH release by administering a potent and specific opiate-receptor antagonist, naltrexone, during the infusions.
Our observations indicate that, despite the continuous infusion of a dosage of 5a-dihydrotestosterone that significantly suppresses LH pulse frequency, co-administration of an opiate-receptor antagonist effectively reinstates LH pulse frequency to control levels. Moreover, during the infusion of a suppressive dose of estradiol-1 73, opiate receptor blockade significantly augments LH pulse frequency and increases LH peak amplitude to control levels.
Thus, the present studies in normal men demonstrate for the first time that the selective inhibitory action of a pure androgen on LH pulse frequency is effectively antagonized by opiate-receptor blockade. This pivotal oW servation indicates that opiatergic and androgen-dependent mechanisms specifically and coordinately control the hypothalamic pulse generator for gonadotropin-re-leasing hormone (GnRH). Moreover, endogenous opiate systems susceptible to blockade by naltrexone also interact significantly with estrogen's negative feedback regulation of LH peak amplitude.
We conclude that the negative feedback actions of gonadal steroids are integrally coupled to endogenous opiate pathways and that such functional coupling is ultimately expressed at least in part at the level of the hypothalamic pulse generator for GnRH. These observations suggest a model for the proximate regulation of gonadotropin secretion in man, in which the regulatory actions of two major inhibitory systems-opiates and gonadal steroids-are effectively integrated by neural mechanisms.
Introduction
Narcotic drugs and endogenous opiate peptides inhibit the elaboration of luteinizing hormone (LH)' by the hypothalamic-pituitary axis in the male and female ofseveral mammalian species (1-1 1). Moreover, the administration of opiate-receptor antagonists alone significantly amplifies the pulsatile mode of LH release, with attendant increases in the frequency and peak amplitude ofboth immunoactive and biologically active LH pulses (1 1-15) . The ability of opiate-receptor antagonists to enhance episodic LH secretion in vivo (11) (12) (13) (14) (15) and to stimulate gonadotropin-releasing hormone (GnRH) secretion from human hypothalamic tissue in vitro (16, 17) has suggested that the inhibitory action of endogenous opiates is exerted at the level of the hypothalamic pulse generator for GnRH.
Gonadal sex steroids also significantly regulate properties of pulsatile gonadotropin release under physiological conditions (18) (19) (20) (21) . In particular, the negative feedback actions of androgen and estrogen can selectively influence either the frequency or the amplitude of the LH pulse signal (22) (23) (24) (25) (26) (27) Serial blood sampling was performed after placebo and naltrexone ingestion in three separate sessions: under basal conditions (control infusions, six men); during infusion of 5a-dihydrotestosterone (the same six men); and during infusion of estradiol-17fB (four of the six men).
Sessions were I mo apart to allow recovery of the gonadal axis. The steroids were administered by continuous intravenous infusions maintained over 4.5 d. 48 gg of estradiol and 7 mg of Sa-dihydrotestosterone were administered per day as described by others (31, 32) . Chromatographically pure steroids (assessed by high pressure liquid chromatography) were dissolved in sterile ethanol, which was diluted in 5% dextrose in water immediately before infusion. One liter of 5% dextrose in water was infused continuously every 12 h after the addition of 0.1 ml of stock steroid solution (100% ethanol). A uniform rate of infusion was maintained with an infusion pump (Volumetric 927; Imed Inc., San Diego, CA). Tygon tubing was used to minimize nonspecific steroid adsorption, which was monitored by radioimmunoassay of the effluent (recovery 85-97% at the catheter tip). After 72 h of steroid infusion, placebo diluent was administered orally and blood was sampled for 12 h (0900-2100) at 20-min intervals to characterize pulsatile LH release. After 96 h ofsteroid infusion, naltrexone elixir(I mg/kg) was administered orally and blood was sampled again for 12 h (0900-2 100) at 20-min intervals. To assess steady state blood levels of sex steroid hormones, blood was also sampled before hormone infusion and every 12 h during the 4.5 d. All blood sampling was performed in the arm contralateral to the infusion.
Blood samples withdrawn from the indwelling intravenous needle were allowed to clot at room temperature, and the serum was stored at -20'C for subsequent immunoassay. Samples from an individual's complete study (all sessions) were analyzed in the same assay to eliminate interassay variability. Serum immunoactive LH concentrations were measured in triplicate by a modification of the method of Odell et al. (33) , with the reagents described previously (34) . Additional pools of serum were assayed nine times each to define the intraassay variability precisely at multiple points along the displacement curve, since our analysis of pulsatile LH secretion employed intraassay variance that was relevant to the individual subject (see below). In the present studies, the intraassay coefficients of variation were 8.5% for LH concentrations of 2-4 mIU/ml, 7.3% for LH values of 4-8 mIU/ml, and 6.5% for LH levels of 8-12 mIU/ml. Serum concentrations of testosterone, estradiol, Sa-dihydrotestosterone, and 5a-androstan-3a, l7fl-diol were determined by radioimmunoassay after celite chromatography exactly as previously described (35, and Samojlik, E., M. A. Kirschner, D. Silber, G. Schneider, and N. H. Ertel, manuscript submitted for publication).
The plasma LH secretion profiles were analyzed for significant fluctuations by a computerized, pulse-detection algorithm modified from that of Santen and Bardin (20) . This method estimates the area under the LH concentrations vs. time curve and the fractional amplitude of individually significant pulses (given as percentage above preceding nadir). Our modification requires that a significant pulse exhibit an amplitude at least four times the individual intraassay coefficient ofvariation (instead of simply 20% as originally described). This somewhat more stringent criterion for an LH pulse minimizes the false-positive error rate for pulse enumeration (15) . We used this means of pulse analysis except where noted otherwise, when we compared results with the independent pulse-detection method of Clifton and Steiner (36) as modified by us (15) . Interpulse (smoothed base line) LH concentrations were computed by the program of Merriam and Wachter (37) . Although sampling at 20-min intervals can underestimate absolute LH pulse frequency compared with more rapid rates of sampling (38), the present assessment of large amplitude LH pulses at a uniform sampling rate does permit us to evaluate relative changes in LH pulse frequency in relation to specific hormonal effects.
Data are presented as mean±SEM and were analyzed by withinsubject comparisons by the use ofa paired two-tailed t test with correction for repeated measures as appropriate. Significant effects were construed for P . 0.05.
Results
Characterization of pulse frequency changes. The infusion of 5acdihydrotestosterone significantly reduced LH pulse frequency in these men from a mean of 3.5±0.3 pulses/12 h (mean±SEM) to 2.0±0.2 pulses/12 h (P = 0.003), when pulse frequency was estimated by the modified method of Santen and Bardin. On the other hand, the infusion of estradiol did not significantly alter LH pulse frequency (Fig. 1) .
Under conditions in which dihydrotestosterone significantly suppressed LH pulse frequency, the co-administration of naltrexone was able to significantly increase pulse frequency from 2.0±0.2 pulses/12 h to 4.7±0.2 pulses/12 h (P = 0.005) (Fig.  1) . Moreover, naltrexone restored LH pulse frequency in the presence of continued androgen infusion to a level that was not significantly different from that observed after naltrexone administration during control infusions.
Naltrexone also significantly stimulated LH pulse frequency during estradiol infusion, with an increase from 3.5±0.25 to 5.3±0.22 pulses/12 h (P = 0.001) (Fig. 1) Fig. 1 .
When all LH data were analyzed by the independent pulsedetection algorithm of Clifton and Steiner (36, 15) , the inferred alterations in LH pulse frequency were corroborated (Fig. 2) rored those for 12-h integrated LH levels. In particular, the arithmetic mean of basal serum LH concentrations (millfinternational units per milliliter±SEM) during control infusions was 8.15±0.83 (and 9.69±1.07 after naltrexone, P = 0.002), which declined significantly to 6.40±0.15 (10.69±1.33 after naltrexone, P= 0.003) during estradiol infusion, and to 4.96±0.57 (7.02+1.41 after naltrexone, P = 0.006) during 5a-dihydrotestosterone infusion. Note that during steroid suppression naltrexone significantly increased mean serum LH concentrations in these subjects to levels not significantly different from control (basal).
Androgen and estrogen infusions affected the interpulse basal levels ofLH and properties of LH pulse amplitude in distinctive ways (Fig. 4) . In particular, dihydrotestosterone administration effectively reduced interpulse basal levels of immunoactive LH (P = 0.01 vs. basal) but notably did not significantly influence properties of LH pulse amplitude, whether considered as fractional pulse amplitude (percentage above nadir), incremental pulse amplitude (millhinternational units per millimeter increase above nadir), or absolute LH peak values (milliinternational units) (Fig. 4) . Despite continuous infusion of dihydrotestosterone, naltrexone administration was associated with a significant rise in peak LH concentrations (P = 0.03) and interpulse basal values (P = 0.08).
In contrast to these effects of dihydrotestosterone, estradiol reduced all parameters of LH pulse amplitude: percentage LH pulse amplitude (P = 0.05 vs. basal), incremental pulse amplitude (P = 0.02 vs. basal), or peak LH pulse amplitude (P = 0.01 vs. basal), but did not significantly suppress interpulse basal LH concentrations (Fig. 4) . Some of these suppressive effects of estradiol were significantly antagonized by naltrexone, which increased peak LH pulse amplitude (P = 0.02) and interpulse basal LH concentrations (P = 0.004). Properties of LH Pulse Amplitude
The typical patterns of altered pulsatile LH secretion observed in these studies are illustrated for one subject in Fig. 5 .
Steroid hormone concentrations in blood during the infusions. As shown in Fig. 6 , serum concentrations of 5a-dihydrotestosterone rose significantly during the infusion of this steroid, reaching stable concentrations within 36 h. For the remaining infusion, 5a-dihydrotestosterone concentrations averaged 3.06 ng/ml, compared with 0.89±0.04 ng/ml basally (normal range, 0.4-1.2 ng/ml). Concentrations of testosterone and estradiol-17(3 did not change significantly over time but continued to exhibit significant AM-PM diurnal variation throughout the 4.5 d of the infusion, with lower PM values (P < 0.01).
When estradiol-17(3 was infused, its serum concentrations increased approximately twofold above base line within 24 h (P < 0.01) and remained at this level thereafter (Fig. 6) . During estrogen infusion, serum concentrations of testosterone and 5a-dihydrotestosterone did not change significantly at any time but did exhibit significant AM-PM diurnal variation throughout, with lower PM values (P < 0.01).
Circulating concentrations of 5a-androstan-3a, 17fl-diol, a major tissue metabolite of 5a-dihydrotestosterone, were also measured in three men by the use of samples collected basally and at 12-h intervals during 5a-dihydrotestosterone infusion. As depicted in Fig. 6 , serum concentrations of this 3a-reduced metabolite increased to a transient peak value at 24 h and then declined gradually to stably elevated levels during the remaining 60 h.
Our serial measurements of the principal circulating gonadal steroids of exogenous and endogenous origins thus document the attainment of equilibrium during the infusions. Moreover, these measurements also demonstrate that the doses of steroids infused did not act pharmacologically to suppress the spontaneous diurnal variations characteristic of endogenous steroids. 17/B-diol (bottom, right) was measured as a major metabolite of 5a-dihydrotestosterone.
Discussion
We have demonstrated that the specific inhibitory action of a pure (nonaromatizable) androgen on LH pulse frequency is effectively antagonized by opiate-receptor blockade. This pivotal inference was corroborated by two independent algorithms for enumerating LH pulses objectively. Thus, we conclude that endogenous opiate systems are functionally coupled to androgen's negative feedback control of episodic LH secretion in man.
In these studies, we chose a dosage of 5a-dihydrotestosterone that selectively suppresses LH pulse frequency without decreasing LH pulse amplitude (32, and, present study), and a dose of naltrexone that antagonizes exogenous opiate challenge for more than 24 h without exerting any discernible agonist effects (15, 39, 40 We infused Sa-dihydrotestosterone, a C19-androgen saturated in the A-ring, because, unlike testosterone, this reduced androgen cannot undergo metabolic conversion to known estrogens (49) . In vivo, endogenous Sa-dihydrotestosterone enters hypothalamic or pituitary cells from the circulation or is generated in situ from available testosterone (23, 50, 51) . When we infused exogenous Sa-dihydrotestosterone at a rate equal to the daily blood production rate of testosterone in normal men (52, 53) , there was a two-to threefold elevation of serum levels of Sa-dihydrotestosterone and its major 3a-reduced metabolite, Sa-androstan-3a, 17j3-diol. Thus, although brain concentrations of 5a-dihydrotestosterone cannot be determined under these condi- tions in the human, we presume they increased and consequently influenced gonadotropin secretion. The alternative possibility that infused 5a-dihydrotestosterone altered LH release indirectly by displacing endogenous testosterone from its plasma binding sites is unlikely under these equilibrium conditions, since injected 5a-dihydrotestosterone actually decreases plasma free testosterone concentrations in men within 24-48 h (54) . As important, the selectivity of this infusion schedule in suppressing LH pulse frequency without reducing LH pulse amplitude closely mimics the effects of low-dosage (but not pharmacological dosage) androgen replacement in other species, such as the rodent, sheep, and Rhesus monkey (55) (56) (57) .
In contrast, infusion of estradiol at its blood production rate in normal men (58) significantly attenuated LH pulse amplitude without altering LH pulse frequency. This observation is similar to that reported when estradiol was infused at twice its production rate (32, 59 (25) , we infer that the increase in peak LH pulse amplitude observed after opiate antagonism may result from enhanced release of endogenous GnRH rather than increased pituitary sensitivity to endogenous GnRH. In addition, the high LH peaks may reflect the imposition of LH pulses on increased interpulse base line LH concentrations, which accompanied naltrexone's shortening of the interpulse interval.
The present results permit us to suggest a model offunctional coupling between androgen and opiate mechanisms (Fig. 7) .
We have chosen the most conservative interpretation ofavailable data, recognizing that additional considerations are possible. In this model, the negative feedback actions of pure androgen on the hypothalamic pulse generator are mediated at least in part via intervening (or parallel) inhibitory opiate pathway(s). Since naloxone and naltrexone can inhibit several opiate receptor subtypes, the exact nature of the opiate receptor(s) involved in the control of LH secretion in man cannot be ascertained at present. However, recent studies in the rodent suggest that mu opiate receptors in particular mediate LH release (60) .
In conclusion, the present studies in normal men have demonstrated that the negative feedback action of pure androgen and estrogen are intimately coupled to endogenous opiate pathways. Moreover, such functional coupling is ultimately expressed at the level of the hypothalamic pulse generator for GnRH with Figure 7 . Possible model of the coupling between pure androgen negative feedback mechanisms and the inhibitory endogenous opiate pathway. In this schema, systemically available or locally converted androgen (here designated as 5a-dihydrotestosterone, DHT) acts on brain sites that ultimately stimulate (+) the opiate systems. Activation of the opiatergic pathways in turn leads to suppressed (-) activity of the hypothalamic GnRH pulse generator. The interposition of several arrows indicates that one or more intervening steps may operate within this basic model. In addition, other neuroendocrine systems (e.g., catecholaminergic) could impinge upon these steps, although the exact relationship(s) of such systems to androgen and opiate actions in man cannot be determined at present. The possibility that an opiate-independent pathway of androgen suppression also exists under physiological conditions is denoted by the lateral convex arrow interrupted by a question mark. *Other regulators may also operate at these sites. consequent modulation of specific properties of pulsatile LH release.
